Intellia Therapeutics/$NTLA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Intellia Therapeutics
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Ticker
$NTLA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
403
ISIN
US45826J1051
Website
NTLA Metrics
BasicAdvanced
$994M
-
-$5.21
2.33
-
Price and volume
Market cap
$994M
Beta
2.33
52-week high
$28.18
52-week low
$5.90
Average daily volume
5.4M
Financial strength
Current ratio
4.897
Quick ratio
4.567
Long term debt to equity
10.32
Total debt to equity
15.29
Profitability
EBITDA (TTM)
-530.796
Gross margin (TTM)
-915.80%
Net profit margin (TTM)
-1,154.10%
Operating margin (TTM)
-1,187.36%
Revenue per employee (TTM)
$110,000
Management effectiveness
Return on assets (TTM)
-30.12%
Return on equity (TTM)
-57.92%
Valuation
Price to revenue (TTM)
21.246
Price to book
1.27
Price to tangible book (TTM)
1.27
Price to free cash flow (TTM)
-2.54
Free cash flow yield (TTM)
-39.37%
Free cash flow per share (TTM)
-377.95%
Growth
Revenue change (TTM)
-13.37%
Earnings per share change (TTM)
-2.57%
3-year revenue growth (CAGR)
6.37%
3-year earnings per share growth (CAGR)
0.99%
What the Analysts think about NTLA
Analyst ratings (Buy, Hold, Sell) for Intellia Therapeutics stock.
Bulls say / Bears say
Intellia's CRISPR-based therapy, nexiguran-ziclumeran, received RMAT designation from the FDA for treating ATTR-cardiomyopathy and ATTR-polyneuropathy, potentially expediting its development and approval process. (tipranks.com)
The company initiated dosing in the global Phase 3 HAELO study for NTLA-2002 targeting hereditary angioedema, with enrollment completion expected in H2 2025 and a BLA submission planned for H2 2026, indicating significant progress in its clinical pipeline. (stocktitan.net)
In a Phase I trial, nexiguran-ziclumeran demonstrated an 89% reduction in TTR over 28 days, surpassing competitors like vutrisiran, which achieved a 70% reduction over 45 days, showcasing superior therapeutic efficacy. (tipranks.com)
The commercial outlook for nexiguran-ziclumeran post-approval remains uncertain due to competitive threats in the ATTR-CM space. (tipranks.com)
Intellia faces increasing competition in the ATTR-CM market from companies like Alnylam, which have aggressive development plans, potentially impacting market share. (tipranks.com)
The company has been under significant financial pressure due to concerns around the commercial viability of gene editing therapies and a financing overhang. (tipranks.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
NTLA Financial Performance
Revenues and expenses
NTLA Earnings Performance
Company profitability
NTLA News
AllArticlesVideos
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
GlobeNewsWire·5 days ago
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course
Benzinga·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Intellia Therapeutics stock?
Intellia Therapeutics (NTLA) has a market cap of $994M as of June 20, 2025.
What is the P/E ratio for Intellia Therapeutics stock?
The price to earnings (P/E) ratio for Intellia Therapeutics (NTLA) stock is 0 as of June 20, 2025.
Does Intellia Therapeutics stock pay dividends?
No, Intellia Therapeutics (NTLA) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Intellia Therapeutics dividend payment date?
Intellia Therapeutics (NTLA) stock does not pay dividends to its shareholders.
What is the beta indicator for Intellia Therapeutics?
Intellia Therapeutics (NTLA) has a beta rating of 2.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.